Wegovy is a Novo Nordisk semaglutide therapy for chronic adult weight management.
Competing Products
Novo Nordisk
Novo Nordisk A/S, a Danish pharmaceutical company, specializes in diabetes care, growth disorders, and hormone therapies globally.
Novo Nordisk A/S, a Danish pharmaceutical company, specializes in diabetes care, growth disorders, and hormone therapies globally.
Novo Nordisk A/S, founded in Denmark, is a leading pharmaceutical company specializing in diabetes care, haemostasis management, growth disorders, and hormone replacement therapy. The company's core mission is to drive change to defeat diabetes and other serious chronic conditions. Novo Nordisk offers a range of products including insulin delivery systems and educational materials, aiming to make healthcare accessible and affordable worldwide.
Notable figures associated with Novo Nordisk include its board members and executive leadership who have steered the company to global prominence. The company has achieved significant milestones such as demonstrating superior treatment outcomes in haemophilia A through its Mim8 trials. With substantial investments in expanding manufacturing capacity in the US, Novo Nordisk continues to impact global health positively by prioritizing chronic disease management and innovative treatment solutions.
Companies similar to Novo Nordisk include Enveda Biosciences, Leal Therapeutics, Novartis and Lundbeck.
Novo Nordisk was founded in 1923.
Novo Nordisk's headquarters is located in Copenhagen, Capital Region of Denmark, DK.
Novo Nordisk's most recent funding round was for $22M (USD) in December 2018.
As of Dec 5, 2018, Novo Nordisk has disclosed funding of $22M (USD). Undisclosed round amounts are excluded.
Novo Nordisk has 55,185 employees as of Feb 6, 2024.
Lundbeck
lundbeck.com